Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
meeting entities : Oncolytics biotech inc. save search
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: 0.0%
biotech fda breast cancer for meeting trial submission
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
Published: 2023-05-31 (Crawled : 16:00) - biospace.com/
INAB | $1.03 -0.96% -0.97% 150K
|
|
| O: 0.35%
H: 6.57%
C: 5.19%
VCYT | News | $19.92 0.45% 0.45% 510K
|
Health Technology
|
| O: -0.43%
H: 3.05%
C: 1.21%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.81%
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: -0.09%
H: 2.57%
C: 1.13%
GERN | $3.57 2.0% 1.96% 6.6M
|
Health Technology
|
| O: 0.6%
H: 2.1%
C: -2.1%
asco cancer meeting set
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations
Published: 2023-05-26 (Crawled : 15:00) - prnewswire.com
DAWN S | $15.18 -8.77% -9.62% 4.6M
|
Professional, Scientific, and T...
|
| O: 0.33%
H: 4.21%
C: 3.06%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: -18.22%
LEGN | News | $45.205 -4.73% -4.97% 1.1M
|
Health Technology
|
| O: 0.35%
H: 0.63%
C: -0.58%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: 0.07%
H: 2.53%
C: 1.23%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.45%
H: 0.79%
C: -1.17%
asco
Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract
Published: 2023-05-25 (Crawled : 22:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: -18.22%
biotech breast asco positive cancer meeting trial
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders - May 10, 2023
Published: 2023-05-10 (Crawled : 12:20) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.0%
H: 1.84%
C: 0.0%
biotech meeting results
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Published: 2023-05-10 (Crawled : 11:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.0%
H: 1.84%
C: 0.0%
biotech meeting results
Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting
Published: 2023-04-26 (Crawled : 00:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -0.88%
H: 15.18%
C: 13.39%
biotech breast presentation asco cancer meeting trial
Oncolytics Biotech® Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General Meeting of Shareholders
Published: 2023-04-12 (Crawled : 11:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.63%
H: 2.68%
C: 0.89%
biotech management meeting
Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort
Published: 2022-11-10 (Crawled : 14:20) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 5.06%
H: 6.42%
C: 4.81%
biotech meeting response cancer pancreatic
Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting
Published: 2022-11-07 (Crawled : 13:20) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 9.52%
H: 10.87%
C: 8.7%
biotech meeting response results cancer study pancreatic phase 1
Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting
Published: 2022-10-05 (Crawled : 17:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.77%
H: 0.76%
C: -3.05%
biotech immunotherapy meeting cancer
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
Published: 2022-06-17 (Crawled : 16:00) - biospace.com/
SEOVF | $0.3252 15.67% 20K
|
Health Technology
|
| O: 7.05%
H: 7.71%
C: 6.06%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.03%
H: 11.24%
C: 10.09%
DMAC | $2.5 3.31% 3.2% 7.4K
|
Health Technology
|
| O: 0.48%
H: 7.18%
C: 2.87%
biotech meeting results
Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting
Published: 2022-05-04 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 2.16%
H: 2.11%
C: 0.7%
biotech potential cancer breast cancer biomarkers
Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting
Published: 2022-05-02 (Crawled : 12:20) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.0%
H: 6.06%
C: 5.3%
biotech presentation cancer breast cancer
Oncolytics Biotech® Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting
Published: 2022-04-08 (Crawled : 19:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -0.64%
H: 7.69%
C: -0.64%
biotech
Oncolytics Biotech® Announces Positive Long-Term Survival Data from Phase 1b Glioblastoma Multiforme Trial at the AACR Annual Meeting
Published: 2022-04-08 (Crawled : 18:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -0.64%
H: 7.69%
C: -0.64%
biotech trial positive phase 2b glioblastoma
Oncolytics Biotech® Announces Upcoming Poster Presentation at the AACR Annual Meeting
Published: 2022-03-09 (Crawled : 13:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 8.72%
H: 1.23%
C: -1.85%
biotech pos ces presentation iot
Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting
Published: 2022-03-09 (Crawled : 13:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 8.72%
H: 1.23%
C: -1.85%
biotech phase 1b phase 1 roof iot phase 2b
Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematology Annual Meeting
Published: 2021-12-15 (Crawled : 12:30) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -0.63%
H: 0.64%
C: -1.27%
biotech ema presentation preclinical iot pre-clinical
Oncolytics Biotech® Announces Annual General Meeting
Published: 2021-04-30 (Crawled : 12:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -0.65%
H: 1.64%
C: 0.33%
biotech iot
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.